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COST AND OUTCOMES OF THE DIABETES CLINIC IN A
COMMUNITY HOSPITAL, MAE HONG SON,THAILAND
Ploylearmsang C1,Thakamphu L2
1Mahasarakham University, Mahasarakham, Mahasarakham,Thailand;
2Lampang Provincial Public Health Ofﬁce, Lampang, Lampang,Thailand
OBJECTIVES: To determine cost and outcomes of a diabetes
clinic in a community hospital of Mae Hong Son Province in
1999. METHODS: A retrospective study, from the provider
viewpoint, was performed by collecting three groups of annual
operating cost; labour cost (LC), drug and medical supplies cost
(MC), and diagnostic cost (DC). The clinic contained of behav-
ioral group counseling about diet, drug, exercise and foot-care
by nurses, pharmacist and self-help group. At the end of the
study, outcomes were evaluated by the number of patient who
achieved in the fasting blood sugar (FBS) of 126mg/dL without
any severe complications and/or the number of patient with
adherence for follow up visits. RESULTS: Results showed that
total operating cost of diabetes clinic was 193,244.64 Baht with
a proportion of LC:MC:DC of 2.36 :5.55 :1. Drug and medical
supplies accounted for more than 60% of total operating cost.
The unit cost of diabetes clinic was 1932.45 Baht per patient. In
total, 62 patients with FBS control and 71 patients with adher-
ence for follow-up were found from all of 100 diabetic patients
in the clinic. A total of 33 successful patients with both FBS
control without severe complications and having adherence were
found. Uncontrol FBS and loss from follow up were the failures
that affected to the cost through drug and medical supplies
overuse and the number of unwanted admissions. CONCLU-
SIONS: Drug and medical supplies accounted for the highest cost
of the clinic. To reduce cost of drug and medical supplies overuse
and increase the outcomes of the clinic, drug and self-care per-
sonal counseling by pharmacist could be a good procedure for
solving the problem. To evaluate the efﬁciency of the clinic, cost
and outcomes were the needed indicators.
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OBJECTIVES: The Study TO Prevent Non-Insulin Dependent
Diabetes Mellitus (STOP-NIDDM) demonstrated that acarbose
therapy over 3.3 years delays or prevents the development of
type-2 diabetes as well as cardiovascular (CV) events in persons
with impaired glucose tolerance (IGT). The aim of the present
study is to assess the economic advantage of these clinical results
for the German health care system. METHODS: A cost-
effectiveness-analysis from the German payers’ perspective was
conducted. The outcome measure was cost per transition to dia-
betes prevented or delayed. Analyses were conducted for the
total population (acarbose (N = 682) and placebo (N = 686)),
and subgroups at high risk for CV disease, for diabetes or both.
Cost data were derived from published sources and adjusted to
the year 2003 where necessary. Future costs and beneﬁts were
discounted by 5%. Acarbose therapy costs and the costs for man-
aging new cases of diabetes, hypertension, and CV events were
taken into account. Only direct healthcare costs were considered.
RESULTS: For the total population treated over 3.3 years, the
incremental cost-effectiveness-ratio was 772€ per case of dia-
betes delayed. For all high-risk subgroups, acarbose treatment
was the dominant treatment option: Cost savings per person in
the subgroup at high risk for CV disease, for diabetes and for
both CV disease and diabetes were 674€, 42€ and 408€ respec-
tively over 3.3 years. These results were robust to sensitivity
analyses. CONCLUSIONS: In addition to the signiﬁcant clinical
beneﬁts observed with acarbose therapy in pre-diabetic persons,
the cost-effectiveness model estimated potential cost savings to
the German healthcare system in those persons at high risk for
diabetes and / or cardiovascular events. For the total population,
acarbose therapy was estimated to be cost-effective.
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OBJECTIVES: Metformin (plus standard lifestyle advice) or
intensive lifestyle changes (ILC) reduced the risk of developing
Type-2 diabetes by 31% and 58% versus standard lifestyle
advice (control) respectively, in subjects with impaired glucose
tolerance (IGT) in the Diabetes Prevention Program (DPP). We
adapted a validated, peer-reviewed, published diabetes preven-
tion model to assess the cost-effectiveness of DPP interventions
in a Spanish setting. METHODS: The published Markov model
simulated 3 states; patients progressed from “IGT” to “Type-2
diabetes” and “death”. Probabilities were derived from the DPP
and published Spanish data. Life expectancy (LE) was calculated
for each treatment arm. Spanish-speciﬁc direct costs of imple-
menting DPP interventions and of diabetes were retrieved from
published sources. Total costs/patient (TC) and costs/life-year
gained were calculated. LE was discounted at both 0 and 3%
annually, while costs were discounted at 3% annually in accor-
dance with current Spanish guidelines. Extensive sensitivity
analyses were performed. RESULTS: Both interventions
improved LE but increased TC versus control. Mean improve-
ments in non-discounted LE were 0.33 and 0.87 years for met-
formin and ILC, respectively. TC were increased by 626€ and
8784€/patient with metformin or ILC respectively, with incre-
mental costs/life-year gained (LYG) (TC and LE discounted 3%
annually) of 3913€ and 22,523€ for metformin or ILC versus
control, respectively. Results were most sensitive to the costs of
implementing ILC (in particular, the costs associated with dieti-
cians). CONCLUSIONS: Metformin was cost-effective, and the
initial costs of pharmacological intervention in prediabetic indi-
viduals should not deter healthcare systems from implementing
diabetes prevention programs. ILC was towards the upper limits
of what is generally considered good value for money in Spain
(i.e. <30,000€/LYG). If the role of lifestyle case managers was
played by less expensive personnel (e.g. a ﬁtness trainer), the
incremental cost-effectiveness ratio for ILC versus control could
be as low as 9185€/LYG.
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OBJECTIVES: To assess the cost-effectiveness of acarbose in the
management of patients with impaired glucose tolerance (IGT)
in Sweden using the multinational, randomised, placebo-
controlled STOP-NIDDM trial, in which patients with IGT
treated with acarbose experienced signiﬁcant reductions in the
incidence of type-2 diabetes and cardiovascular (CV) events.
METHODS: A disease state transition model using data from
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the STOP-NIDDM trial was developed to replicate the manage-
ment of IGT patients over the 3.3-year trial period. The cost-
effectiveness measures were cost per patient free of diabetes and
cost per month free of diabetes. Analyses were performed for the
total trial population and three subgroups: high risk for diabetes,
high risk for CV disease and high risk for combined diabetes-CV
disease. Total direct costs were calculated using standard sources
and published literature. Costs and outcomes were discounted 
at 3% and extensive sensitivity analyses were conducted.
RESULTS: The incremental cost per patient free of diabetes
(month free of diabetes) was 3032€ (136€) and 829€ (35€) 
for the total study population and high risk diabetes sub-
group respectively. Acarbose treatment dominated (i.e. was 
more effective, less costly) placebo in subgroups at high CV 
risk and high combined diabetes-CV risk. Deterministic sensi-
tivity analyses showed that the discount rate for costs and the
probability of transition to diabetes had the largest impact on
results. CONCLUSIONS: Acarbose treatment signiﬁcantly
reduces the incidence of diabetes and CV events in IGT patients.
This clinical advantage is expected to lead to reductions in
healthcare costs that exceed the acquisition cost of acarbose, thus
resulting in overall cost savings in high risk subgroups for CV
disease and combined diabetes-CV disease. For the total study
population and the high risk diabetes subgroup, savings from
fewer cases of diabetes and CV events partly offset the cost of
acarbose.
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OBJECTIVE: To estimate the cost of intensive treatment of DM
T2patients (insulin therapy and combined treatment with insulin
and oral hypoglycemic agents (OHAs)). METHODS: The study
was conducted for 24 weeks and included 4 visits. In total, 153
patients in DM T2 were examined (65% women and 35% men).
The average age was 56.7 years, the duration of the disease was
9.5 years. The cost of treatment included: the cost of patient
observation, daily test monitoring, diagnostic manipulations and
consultations and cost of the medicines used. Analysis of expen-
ditures was conducted using the incremental cost estimation
method that takes into account only the changing quantities.
RESULTS: All the patients were divided into two groups in
dependence on the result obtained: group 1 (85pts.), with a level
of HbA1c < or = 7.0%, and group 2 (68pts.), with a level of
HbA1c > 7% (p = 0.2784). In group 1, 60 patients received
insulin monotherapy and 25—a combination of insulins and
OHAs. In group 2, these subgroups counted 34 and 34 patients,
respectively. The intensive treatment was associated with
increases in the patient management costs by USD 0.89/patient
in group 1 and USD 0.78/patient group 2. The cost of treatment
increased because of an increase in the consumption of insulin
and expenditures on intensive observation. CONCLUSION:
The cost of achieving the clinical efﬁcacy criteria in the group
where optimal glycemic control was achieved turned out to be
comparable with the cost of managing patients in the group
where this control was not achieved. However, in group 1, a
decrease in the cost of treatment of concurrent diseases was
noted. Thus, proof was obtained: glycemic control is the major
determinant of the development of cardiovascular complications
of advanced DM.
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CONTINGENT VALUATION OF AN INHALED DELIVERY
SYSTEM FOR INSULIN
Sadri H, MacKeigan L, Einarson TR, Leiter LA
University of Toronto,Toronto, ON, Canada
OBJECTIVES: Various delivery systems for inhaled insulin (INI)
are under development. However, they will likely be substantially
more expensive than subcutaneous insulin (SCI). Whether this
increased cost is justiﬁed is an important question which can be
addressed through Contingent Valuation (CV), a survey tech-
nique that elicits individuals’ preferences for non-marketed prod-
ucts in terms of the amount they would be willing-to-pay. The
purpose of this study was to assess diabetic (DM) patients’ pref-
erence and willingness-to-pay (WTP) for INI. METHODS: A
face-to-face CV survey was administered to 96 type-1 and type-
2 adult DM patients at St. Michael’s Hospital (Toronto, Canada)
who were taking insulin and/or oral antihyperglycaemic drugs.
Standardized information about INI and SCI was provided by
video, and participant’s WTP was elicited using “payment scale”
method, along with socioeconomic and clinical data. Published
data was used to deﬁne INI attributes. The CV questionnaire
received expert review for content validity and was pilot tested
with 22 patients. RESULTS: Participants were 51.8 ± 13.4 years
old, and had DM for an average of 11.8 ± 7.8 years; 77 had
type-2 and 19 had type-1 DM. Signiﬁcantly more participants
(89%) preferred INI over SCI (P < 0.01). The mean monthly
WTP for INI ($153.70 ± $99.90) was signiﬁcantly more than
typical SCI cost of $50 (P < 0.01). A greater proportion of type-
2 patients (n = 72/77) preferred INI than did type-1 patients 
(P < 0.001). The mean WTP for INI in type-2 subgroup ($177.10
± $91.60) was signiﬁcantly more compared to type-1 ($154 ±
$66.6, P = 0.025). Signiﬁcantly more participants who were not
on insulin preferred INI compared to participants using insulin
(P < 0.001). Multiple-regression analysis showed strong associ-
ation between participants’ income and insulin experience and
their WTP for INI (P < 0.001). CONCLUSIONS: DM patients
prefer INI over SCI and are willing-to-pay signiﬁcantly more per
month than the cost of SCI. Preferences are stronger in type-1
patients DM and those with prior insulin experience.
PDB25
QUALITY OF LIFE IN SUBJECTS WITH AND WITHOUT TYPE-2
DIABETES MELLITUS
Perelli Cippo P, Scalone L, Micheletti S, Mantovani LG
University of Milan, Milan, Italy
OBJECTIVES: Type-2 diabetes mellitus is a chronic and pro-
gressive disease with a negative impact on quality of life. Objec-
tives of the present study were to describe Health-Related
Quality of life (HRQOL) in type-2 diabetes mellitus and to
compare the health state between diabetic and non-diabetic sub-
jects. METHODS: Type-2 diabetes mellitus patients were
selected from a representative sample of the Italian general pop-
ulation aged from 40 to 79 years enrolled in a population based
naturalistic prospective survey. We matched each of them by age
and sex with a non-diabetic subjects. The EuroQoL (EQ-5D), a
self-administered generic questionnaire, completed during the
enrolment visit, was used to evaluate HRQOL. RESULTS: We
analyzed two groups of 157 subjects each (diabetic and non-
diabetic group). The mean age was 63.0 years, 94 (59.9) were
male. Diabetic patients reported more problems than non-
diabetic subjects in the physical sphere, speciﬁcally for mobility
